论文部分内容阅读
目的探讨孟鲁司特对咳嗽变异性哮喘(cough variant asthma,CVA)患儿支气管肺泡灌洗液(BALF)中的嗜酸性粒细胞(EOS)计数的调节作用。方法选择湖州市中心医院门诊及住院的CVA患儿81例,分成随机分为对照组(n=37)和治疗组(n=44)。对照组给予常规治疗,治疗组在常规治疗基础上加口服孟鲁司特钠咀嚼片5 mg,每日1次,治疗12周。比较2组治疗前后肺功能与BALF-EOS比例变化。结果治疗前对照组和治疗组EOS比例分别为(4.65±0.76)%和(4.51±0.67)%,2组比较差异无统计学意义(P>0.05);治疗后对照组和治疗组EOS比例分别为(3.04±0.58)%和(1.93±0.51)%,2组比较差异有统计学意义(P<0.01)。结论孟鲁司特钠可以明显降低CVA患儿BALF-EOS水平。
Objective To investigate the regulatory effect of montelukast on eosinophil count (EOS) in bronchoalveolar lavage fluid (BALF) in children with cough variant asthma (CVA). Methods Eighty-one patients with CVA in outpatient department and hospitalized in Huzhou Central Hospital were randomly divided into control group (n = 37) and treatment group (n = 44). The control group was given routine treatment. The treatment group was given oral montelukast sodium chewable tablets 5 mg once daily for 12 weeks on the basis of routine treatment. The changes of pulmonary function and BALF-EOS ratio before and after treatment were compared between the two groups. Results The proportions of EOS in control group and treatment group before treatment were (4.65 ± 0.76)% and (4.51 ± 0.67)%, respectively. There was no significant difference between the two groups (P> 0.05) (3.04 ± 0.58)% and (1.93 ± 0.51)%, respectively. The difference between the two groups was statistically significant (P <0.01). Conclusion Montelukast sodium can significantly reduce the level of BALF-EOS in children with CVA.